Background
Ivuxolimab (PF-04518600) is an activating monoclonal antibody to TNFRSF4 (OX40, CD134), which mimics the binding of the ligand, TNFSF4 (OX40L, CD252), to stimulate proliferation of T-cells and enhance an anti-tumor response• Targeting co-stimulatory molecules in autoimmune disease., PMID:32939077• OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target., PMID:38236520• The role of OX40 ligand/OX40 axis signalling in atopic dermatitis., PMID:38836560• Target-conditioned diffusion generates potent TNFR superfamily antagonists and agonists., PMID:39636970• An OX-Tra'Ordinary Tale: The Role of OX40 and OX40L in Atopic Dermatitis., PMID:38607026• Entry of betaherpesviruses., PMID:31439151• OX40 (CD134) and OX40L., PMID:19760068• Research progress in OX40/OX40L in allergic diseases., PMID:39404736• The OX40-TRAF6 axis promotes CTLA-4 degradation to augment antitumor CD8+T-cell immunity., PMID:37932534• The role of tumor necrosis factor receptor superfamily member 4 (TNFRSF4) gene expression in diagnosis and prognosis of acute myeloid leukemia., PMID:34453673